Literature DB >> 25787322

[Hairy cell leukemia].

S Dietrich1, M Andrulis, T Zenz.   

Abstract

Hairy cell leukemia was initially described as a distinct entity in 1958. It is rare B-cell malignancy characterized by an indolent course. Advances in the treatment and understanding of the biology of hairy cell leukemia have made the disease exquisitely amenable to treatment. This review summarizes the present understanding of hairy cell leukemia with a particular focus on the development of novel and targeted approaches to treatment.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25787322     DOI： 10.1007/s00108-014-3599-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


  54 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses.

Authors:  Thomas M Habermann; Kanti Rai
Journal:  Leuk Lymphoma       Date:  2011-06

3.  BRAF mutations in hairy-cell leukemia.

Authors:  Enrico Tiacci; Vladimir Trifonov; Gianluca Schiavoni; Antony Holmes; Wolfgang Kern; Maria Paola Martelli; Alessandra Pucciarini; Barbara Bigerna; Roberta Pacini; Victoria A Wells; Paolo Sportoletti; Valentina Pettirossi; Roberta Mannucci; Oliver Elliott; Arcangelo Liso; Achille Ambrosetti; Alessandro Pulsoni; Francesco Forconi; Livio Trentin; Gianpietro Semenzato; Giorgio Inghirami; Monia Capponi; Francesco Di Raimondo; Caterina Patti; Luca Arcaini; Pellegrino Musto; Stefano Pileri; Claudia Haferlach; Susanne Schnittger; Giovanni Pizzolo; Robin Foà; Laurent Farinelli; Torsten Haferlach; Laura Pasqualucci; Raul Rabadan; Brunangelo Falini
Journal:  N Engl J Med       Date:  2011-06-11       Impact factor: 91.245

4.  Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.

Authors:  I W Flinn; K J Kopecky; M K Foucar; D Head; J M Bennett; R Hutchison; W Corbett; P Cassileth; T Habermann; H Golomb; K Rai; E Eisenhauer; F Appelbaum; B Cheson; M R Grever
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

Review 5.  Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping.

Authors:  Martin S Tallman
Journal:  Leuk Lymphoma       Date:  2011-04-04

6.  Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence.

Authors:  Monica Else; Claire E Dearden; Estella Matutes; Francesco Forconi; Francesco Lauria; Humayun Ahmad; Susan Kelly; Anandika Liyanage; Vijitha Ratnayake; Jagadeesan Shankari; Ioana Whalley; Daniel Catovsky
Journal:  Leuk Lymphoma       Date:  2011-04-19

7.  Fludarabine and rituximab for relapsed or refractory hairy cell leukemia.

Authors:  Alina S Gerrie; Leslie N Zypchen; Joseph M Connors
Journal:  Blood       Date:  2012-01-05       Impact factor: 22.113

8.  The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.

Authors:  Monica Else; Nnenna Osuji; Francesco Forconi; Claire Dearden; Ilaria Del Giudice; Estella Matutes; Andrew Wotherspoon; Francesco Lauria; Daniel Catovsky
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

9.  Pentostatin induces durable remissions in hairy cell leukemia.

Authors:  P A Cassileth; B Cheuvart; A S Spiers; D P Harrington; F J Cummings; R S Neiman; J M Bennett; M J O'Connell
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

10.  Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.

Authors:  Stephen S Chung; Eunhee Kim; Jae H Park; Christopher Y Park; Omar Abdel-Wahab; Young Rock Chung; Piro Lito; Julie Teruya-Feldstein; Wenhuo Hu; Wendy Beguelin; Sebastien Monette; Cihangir Duy; Raajit Rampal; Leon Telis; Minal Patel; Min Kyung Kim; Kety Huberman; Nancy Bouvier; Michael F Berger; Ari M Melnick; Neal Rosen; Martin S Tallman
Journal:  Sci Transl Med       Date:  2014-05-28       Impact factor: 17.956
View more
  1 in total

Review 1.  [Predictive molecular pathological stratification of hematological neoplasms].

Authors:  M Andrulis
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.